How KaloBios Pharmaceuticals Inc (KBIO) is Bouncing Back from a Brutal Day

KaloBios Pharmaceuticals Inc (KBIO) is staging an incredible comeback from Tuesday's beat-down

by Alex Eppstein

Published on Nov 25, 2015 at 2:38 PM

KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) is the biggest gainer on the Nasdaq this afternoon, bouncing back from Tuesday's brutal 53.6% loss. Specifically, the biotech stock has surged nearly 44% to flirt with $26.60, after the company responded to a delisting notice from the Nasdaq -- triggered by its failure to file a quarterly report -- by saying it "intends to file ... as soon as practicable."

KBIO has been nothing short of incredible this month, since news broke of a huge investment from Turing Pharmaceuticals CEO Martin Shkreli. Relative to its close at $2.07 on Nov. 18 -- the session prior to that development -- the stock has gained 1,185%.

Meanwhile, short sellers have been hitting the eject button at a rapid-fire rate -- while those who haven't are getting killed. During the last two reporting periods, short interest on KaloBios Pharmaceuticals Inc (NASDAQ:KBIO) plummeted close to 35%. At present, 14.1% of the stock's float is still sold short, though it would take less than two sessions to repurchase those positions, at typical volumes.

A Schaeffer's exclusive!

The Expert's Guide

Access your FREE trading earning announcements before it's too late!


  
 

Partnercenter


NEW! Explore Schaeffer’s Partners' deals and get connected to top online brokerages with deals tailored exclusively for our readers.  Get answers to your questions regarding transfer fees, commission rates, programs and available discounts related to online trading services.

MORE | MARKETstories


Research Exposes Shortcut to Stock Market Wins
A simple way to stop picking losers, and start cashing in like Wall Street's elite.
Cannabis Stock Rally Cut Short after Downgrade
Aurora Cannabis did receive a price-target hike from Jefferies, though
Vaccines, China Trigger Roller Coaster Week for Stocks
Moderna's vaccine captured the attention of Wall Street
Research Exposes Shortcut to Stock Market Wins
A simple way to stop picking losers, and start cashing in like Wall Street's elite.